Establishment Labs reports Q2 EPS (62c), consensus (51c)

Reports Q2 revenue $44.1M, consensus $43.1M. “The strong sequential revenue growth of 18.7% in the second quarter is an important achievement as we return to growth. We also saw the tangible results of our efforts to reduce our expense base, with adjusted EBITDA improving to a loss of $4.3 million, less than half the loss we saw in the year ago period,” said Juan Jose Chacon-Quiros, Chief Executive Officer. “Late last month, the U.S. FDA completed the PMA preapproval inspection of our manufacturing facility. We expect approval of Motiva Implants in the United States soon. Our launch in the U.S. will be a watershed event in our journey to transform breast aesthetics and reconstruction. The new standard we have set for clinical and aesthetic outcomes in these categories will now be available to women and surgeons in the largest market in the world. We are on a clear path for global market leadership and have many years of strong and healthy growth ahead of us.”